Related Experiment Videos
In vivo evaluation of epidermal growth factor and transforming growth factor beta 1 in mouse tumor models
S P Robinson1, W C Rose, A Casazza
1Department of Experimental Therapeutics, Bristol-Myers Squibb Co., Wallingford, CT 06492.
Abstract:
The influence of modulating circulating levels of epidermal growth factor (EGF) and transforming growth factor beta 1 (TGF-beta 1) on tumor growth was examined in a variety of mouse models. Removal of the EGF-rich submandibular gland from host mice failed to alter the growth of a variety of human tumor xenografts or a C3H mouse tumor. Infusion of EGF from Alzet minipumps raised circulating EGF levels. However, only the A549 human tumor xenograft showed any significant increase in growth in the presence of EGF infusion and this response was marginal. The growth of Wehi 3BD+ and A549 tumor lines in culture was inhibited by TGF-beta 1. The growth of these lines in vivo, however, was not significantly altered by the administration of TGF-beta 1 via a variety of routes.
Insights
Modulating circulating levels of epidermal growth factor (EGF) and transforming growth factor beta 1 (TGF-beta 1) had minimal impact on tumor growth in mouse models. EGF infusion showed a marginal effect on one xenograft, while TGF-beta 1 inhibited tumor cell growth in vitro but not in vivo.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Epidermal growth factor (EGF) and transforming growth factor beta 1 (TGF-beta 1) are key regulators of cell growth and differentiation.
- Their roles in modulating tumor progression and growth are complex and require further investigation in vivo.
- Understanding these roles is crucial for developing targeted cancer therapies.
Purpose of the Study:
- To investigate the impact of altered circulating levels of EGF and TGF-beta 1 on the growth of various tumors in mouse models.
- To determine if manipulating EGF and TGF-beta 1 can serve as a therapeutic strategy for cancer treatment.
Main Methods:
- Utilized mouse models with modulated circulating EGF levels (submandibular gland removal, EGF infusion via Alzet minipumps).
- Administered TGF-beta 1 through various routes to assess its in vivo effects.
- Evaluated tumor growth of human xenografts (A549) and mouse tumors (C3H, Wehi 3BD+) in vivo and in vitro.
Main Results:
- Removal of the EGF-rich submandibular gland did not affect the growth of tested tumors.
- EGF infusion led to a marginal increase in the growth of the A549 human tumor xenograft only.
- TGF-beta 1 inhibited the in vitro growth of Wehi 3BD+ and A549 tumor lines but showed no significant effect on their in vivo growth.
Conclusions:
- Circulating levels of EGF and TGF-beta 1 do not significantly influence the in vivo growth of the tested tumor models.
- While TGF-beta 1 exhibits in vitro anti-proliferative effects, this activity does not translate to in vivo tumor inhibition.
- Further research is needed to explore alternative mechanisms or combinations for targeting these growth factors in cancer therapy.